proportion of drugs including anesthetics still have no infant labeling. Sufficient research to demonstrate efficacy or safety has simply not been done. Almost 200 yr after Dr. Buchan made his observations, infants are still relatively disadvantaged.

Andrew Davidson, M.B.B.S., M.D., F.A.N.Z.C.A., Royal Children’s Hospital, Melbourne, Australia. andrew.davidson@rch.org.au

References


(Accepted for publication April 6, 2009.)

Anesthesiology 2009; 111:444

Copyright © 2009, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

The Aged Erythrocyte: Key Player in Cancer Progression, but Also in Infectious and Respiratory Complications of Blood Transfusion?

To the Editor:—We read with interest the study of Atzil et al.1 on the deleterious effect of storage of erythrocytes on cancer progression in two tumor rat models. Using different transfusion products, the impact of erythrocytes, leukocytes, and leukocyte-derived soluble factors on host ability to clear circulating cancer cells and host survival rates was assessed. Blood transfusion was found to be an independent risk factor for cancer progression. Surprisingly, aged erythrocytes (9 days and older), rather than leukocytes or soluble factors, mediated the effects. The authors hypothesized that aged erythrocytes may preoccupy host-innate immune effector cells, leaving tumor cells unattended.

Besides cancer progression, other adverse effects of blood transfusion may also be influenced by storage time of erythrocytes. Transfusion of nonleucoreduced aged erythrocytes was found to be associated with an increase in postoperative infectious complications.2,3 To date, the mechanism of this phenomenon is not clear. A role for leukocytes and/or soluble factors in the stored blood products has been suggested. The results of the present study may suggest another mechanism of blood transfusion–related infections. It could be hypothesized that patients transfused with aged erythrocytes may develop a disturbed host immune defense, either via suppression of the interaction of host immune cells with bacteria, or via suppression of cytokine secretion, which may result in a vulnerability to develop pneumonia or other infections. If erythrocytes indeed play a role, this may explain why studies comparing leukoreduced with nonleucoreduced red blood cell transfusions showed no effect on the incidence of infectious complications.4

Besides infectious complications, transfusion of outdated erythrocytes is associated with the onset of acute lung injury,2,5 which may be mediated by biologically active lipids and/or cytokines that accumulate during storage of blood products.6,7 In our laboratory, we performed preliminary experiments with transfusion of healthy rats with stored erythrocytes from the same animal species. Stored erythrocytes resulted in respiratory symptoms and worsening of the condition of the animals, suggestive of acute lung injury. Did the authors of the article under discussion notice any respiratory failure in the animals transfused with stored erythrocytes, as compared with controls transfused with fresh erythrocytes or saline, before the inoculation of the cancer cells?

In conclusion, the authors have pointed to aged erythrocytes as mediators of cancer progression, raising questions about potential other effects of storage of erythrocytes on host immune response. We would like to call for further experimental and clinical studies assessing the role of aged erythrocytes in transfusion-related infectious complications and on transfusion-related acute lung injury.

Alexander P. J. Vlaar, M.D.,* Dirk de Korte, Ph.D., Nicole P. Juffermans, M.D., Ph.D. *Academic Medical Center, Amsterdam, The Netherlands. a.p.vlaar@amc.uva.nl

References


(Accepted for publication April 8, 2009.)

Patient Blood Management and Transfusion

To the Editor:—We have read with great interest both the editorial by Spahn et al.4 in the December issue of ANESTHESIOLOGY. We fully agree with the argumentation, but we want to go further into this debate.

The very well designed animal study of Atzil et al.2 is very interesting, expressing the independent role of blood transfusion in cancer progression and, more precisely, the role of aged erythrocytes more than leukocytes. The editorial of Spahn et al.5 related to this article summarizes brilliantly the numerous disadvantages of homologous blood transfusion.

Red blood cell transfusion is a frequently performed activity in routine anesthetic practice. There are great differences between Euro-
In Reply.—We thank Dr. de Saint Maurice et al. for their comments regarding our editorial view and share their concerns over perioperative deaths as a result of inadequate blood management. We could not agree more with their view that not measuring the hemoglobin concentration consecutively during major hemorrhage is substandard care, as is not treating severe hypovolemia or hypotension in such situations.

This is what patient blood management is all about: patient blood management is based on three pillars: Detecting and treating preoperative anemia, reducing the loss of red blood cells perioperatively, and optimizing the treatment of anemia. Red blood cell transfusions may be administered if all other options have been used and the patient starts showing signs of inadequate oxygenation. Of course, the quick correction of hypovolemia, hypotension, tachycardia, and arrhythmia is an integral part of patient blood management.

It is of utmost importance not to confound the momentary helpful effect of red blood cell transfusion on hypotension and hypovolemia with an outcome benefit. Red blood cell transfusions are indisputably associated with an increase in mortality, increased major adverse cardiac and noncardiac outcome, acute lung injury, nosocomial infection, tumor growth, duration of hospitalization, and cost.

Therefore, there is an urgent need for change, and the Governments of Western Australia and the Canton of Zurich, Switzerland, are to be congratulated again for taking the lead in sustainably implementing patient blood management and thereby improving patient outcome.

Donat R. Spahn, M.D., F.R.C.A., Holger Moch, M.D., Axel Hofmann, M.E., James P. Isbister, M.B., F.R.A.C.P., *University Hospital Zürich, Zürich, Switzerland. donat.spahn@usz.ch

References


